Read full article on Targeted Oncology:
- The FDA has granted SH-110 orphan drug designation (ODD) for the treatment of patients with glioma.
- SH-110 is an oral suspension that provides a liquid form of treatment for patients with glioma who have difficulty swallowing.
- FDA orphan drug designation highlights its role in treating a rare, underserved population.
